OMass raises $310 million in Series C financing with Sanofi Ventures participation

By Public Technologies
  • OMass Therapeutics announced an oversubscribed $310 million (£230 million) Series C financing on October 15, 2026.
  • The biotechnology company develops small-molecule therapeutics in endocrinology and immunology.
  • Bain Capital Life Sciences, Forbion and Novo Holdings co-led the round; existing investor Sanofi Ventures also participated.
  • Proceeds will advance MC2 receptor antagonist OMS1620 through Phase 2 development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
  • Funding will also support initial clinical data for an SLC15A4 inhibitor targeting lupus and other immune-related diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi Ventures published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.